1,001
Participants
Start Date
April 30, 2016
Primary Completion Date
July 31, 2016
Study Completion Date
January 31, 2017
30 µg/strain of Quadrivalent VLP Vaccine
Single dose of non-adjuvanted Quadrivalent VLP Vaccine
60 µg/strain of Quadrivalent VLP Vaccine
Single dose of non-adjuvanted Quadrivalent VLP Vaccine
FluLaval® Tetra (15 µg/strain)
Single dose of a licensed quadrivalent vaccine
Fluzone® High-Dose (60 µg/strain)
Single dose of a licensed trivalent vaccine
Regional Clinical Research (RCR), Endwell
Meridian Clinical Research - Savannah, Savannah
Broward Research Group (BRG), Hollywood
Miami Research Associates (MRA), South Miami
Meridian Clinical Research - Omaha, Omaha
Paradigm Research - Redding, Redding
INC Research Toronto, Toronto
Topstone Research, Toronto
Manna Research, Lévis
Omnispec Clinical Research, Mirabel
Diex Research Montreal, Montreal
McGill University Health Center - Vaccine Study Center (MUHC), Pierrefonds
Diex Research Sherbroooke, Sherbroooke
Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU), Québec
Centre de Recherche St-Louis, Québec
Lead Sponsor
Medicago
INDUSTRY